Abstract Book - 26th ESPU Congress, Joint Meeting with ICCS + SPU + AAP/SOU + AAPU + SFU

09:06 - 09:09

S22-2

(PP)

★

THE VALUE OF URINARY NGF, TGF BETA-1,TIMP-2 LEVELS ON BOTULINUM

TOXIN TYPE A TREATMENT FOR NEUROGENIC DETRUSSOR OVERACTIVITY IN

CHILDREN WITH MYELODYSPLASIA

Tuncay TOP

, Cagri Akin SEKERCI

, Banu ISBILEN BASOK

, Ferruh ISMAN

, Cem AKBAL

, Ferruh SIMSEK

and Tufan

TARCAN

1) Marmara University School of Medicine, Urology, Istanbul, TURKEY - 2) Medeniyet University, Biochemistry, Istanbul,

TURKEY

PURPOSE

The aim of this study is to address the influence of BoNTA treatment on urinary NGF, TGF Beta 1, TIMP-2 levels in

children with myelodysplasia.

MATERIAL AND METHODS

15 patients who have NDOA due to myelodysplasia and treated with intradetrusor BoNTA injection were included in this

prospective one sided Cohort study. Urines of these patients were collected preoperatively and at postoperative first and

third month after BoNTA injection. Urine samples were stored at – 80

C after centrifugation (3000 rpm for 10 minutes).

Urine NGF, TGF-β1 ve TIMP-2 levels were measured by using ELISA method with commercial kit (RayBiotech Inc., ABD).

Results of urodynamic studies, urinary ultrasound and DMSA scintigraphy findings of these patients were analyzed both

before and after BoNTA injection. Simultaneously NGF, TGF Beta 1 and TIMP-2 levels on urine samples were measured.

Influences of BoNTA treatment were evaluated with these parameters.

RESULTS

Mean age of the patients were 7.1 ± 2.5 (5 boys 33 % and 10 girls 66 %, min:2.5-max:11). Urinary TGF Beta 1 and

NGF levels were found significantly decline after BoNTA treatment when compared to preoperative levels (p < 0.05).

TIMP-2 levels were also decline but the results were not significant (Table-1).

Table-1

Before

Treatment

Postoperative

1st Month

Postoperative

3rd Month

p Value

NGF (ng/mg Cr) ±Sd (n:15)

1.62 ±1.63

0.6 ± 0.43

0.73 ±0.66 0.002

TGF beta 1 (ng/mg Cr) ±Sd (n:15) 3.5±3.6

1.2 ± 0.79

1.1± 0.71

0.001

TIMP-2 (ng/mg Cr) ±Sd (n:15)

8.9 ± 5.6

8.2 ± 7.3

7.3 ±3.2

0.63

CONCLUSIONS

These markers may provide easy follow up of patients with myelodysplasia and decrease the need for further invasive

and expensive procedures.